Okufanele Ukwazi Nge-Indian Frankincense
Kuyini i-Boswellia noma iFrankincense yaseNdiya?
I-Boswellia ngumuthi ovela eNdiya. Ukukhishwa okuvela ku-resin yama-gum emagqumeni wesihlahla saseBosswellia kucatshangwa ukuthi kunezinzuzo ezithile zezempilo. I-Boswellia ihlelwa njenge- herb ayurvedic . Kubizwa nangokuthi inhlaka yempepho yaseNdiya.
Yiziphi Izinzuzo Zempilo Ze-Boswellia?
I-Boswellia kucatshangwa ukuthi inezakhiwo zokulwa nokuvuvukala nokuhlambalaza (ubuhlungu obukhulu).
Kukhona ubufakazi obuhle, kodwa hhayi obuqinile besayensi bokusebenzisa i-Boswellia ukuphatha i-asthma engapheli nomdlavuza. Kukhona ubufakazi obucacile besayensi bokusetshenziswa kwawo ukuphatha isifo samathambo, i- osteoarthritis , i-ulcerative colitis, nesifo sikaCrohn. Ngokugcwele, ubufakazi obusekela imiphumela yayo enenzuzo bukhulu.
Kuyini Ukutholakala kwe-Boswellia?
I-Boswellia iyatholakala njenge-capsule noma iphilisi. I-dose ejwayelekile yokunconywa i-300 mg. kuya ku-400 mg., kathathu ngosuku. Noma kunjalo, ukuhlolwa okuphephile kwe-Boswellia akukafundi kahle. Kunconywe ukuthi kulabo abakhetha ukusebenzisa i-Boswellia, umkhiqizo oqukethe i-asidi ye-boswellic ayi-60 kufanele ukhethwe.
Izifundo Ezisekela Izinzuzo Ze-Boswellia
Ngo-2003, ukuhlolwa okungahleliwe, okwenziwe nge-placebo, ukukhishwa kwe-crossover kuhlolisise ukuphepha, ukusebenza, nokubekezela kwe-Boswellia serrata ekhishwa kuziguli ezingama-30 ze- osteoarthritis . Imiphumela eyashicilelwe ePhytomedicine yembula ukuthi iziguli ezingu-15 zathola uBosswel, kanti ezinye ezingu-15 zathola indawo ye-placebo yamaviki angu-8.
Emva kokuhlolwa kokuqala kwenzeka emavikini ayisishiyagalolunye, amaqembu ayenenkathi yokuhlanza (isikhathi esithathayo ukuba umzimba uqede ngokuphelele ukwelashwa). Emasontweni angu-8 alandelayo, iziguli zawela ukuze zithole okuphambene nalokho abanikezwa ngamasonto ayisithupha okuqala. Iziguli ezinikezwe i-Boswellia zonke zibike ukuncipha kwamadolo, ukunyuka kwamadolo, nokwandisa ibanga elihamba phambili.
Ukuvuvukala okuhlangene kwehlile. Kwakungekho ushintsho olubonakalayo kuma-x-ray.
Ngo-2007, abacwaningi bashicilela imiphumela kwi- Indian Journal of Pharmacology kusuka encwadini evulekile, engaba khona, evulekile yenyanga engama-6, isifundo sokuqhathanisa esihlolisise ukuphumelela, ukuphepha nokubekezela kwe-Boswellia serrata okuqhathaniswa ne-valdecoxib (igama elithi Bextra, elikhishiwe emakethe e-US ngo-2005) kweziguli ezingama-66 ezine-knee osteoarthritis. Ubuhlungu, ukuqina, nobunzima ekwenzeni imisebenzi yansuku zonke kwathuthuka kakhulu phakathi kwezinyanga ezimbili zokwelashwa neBosswel futhi ngcono kwaqhubeka kwaze kwaphela inyanga eyodwa ngemuva kokuyeka ukwelashwa. Kube nokuthuthukiswa okuphawulekayo kuziguli eziphathwe nge-valdecoxib ngemva kwenyanga eyodwa yokwelapha, kodwa umphumela onenzuzo awuzange uqhubeke ngemuva kokwelashwa.
Ngonyaka ka-2008, kwakukhona ucwaningo oluhilela u-5-Loxin, i-Boswellia serrata ekhishwayo ehlanganiswa ne-asidi 30% 3-O-acetyl-11-keto-beta-boswellic acid. Kwakukhona iziguli ezingama-75 ezithintekayo esifundweni sezinsuku ezingu-90, ngokusho kwemiphumela eshicilelwe ku- Arthritis Research Therapy . Esikhathini sezinsuku ezingu-90, iziguli zithole i-100 mg. noma 250 mg. we-5-Loxin noma i-placebo. 5-Loxin itholwe ukunciphisa ubuhlungu nokuthuthukisa ukusebenza ngokomzimba ezigulini ze-knee osteoarthritis.
Ngo-2010, i-5-Loxin ne-Aflapin, kokubili evela ku-Boswellia serrata, yayifaniswa ne-knee osteoarthritis. Kwakukhona iziguli ezingu-60 ze-osteoarthritis esifundweni, eshicilelwe kuyi- International Journal of Medical Sciences . Iziguli zitholiwe yi-100 mg. 5-Loxin noma 100 mg. Aflapin noma placebo izinsuku ezingu-90. Kokubili u-5-Loxin no-Aflapin ubuhlungu obukhulu nokusebenza ngokomzimba kakhulu.
Ngo-2011, imiphumela yokuhlolwa kwezinsuku ezingu-30 eyayihlola ukusebenza kwe-Aflapin yokuphatha izimpawu ze-osteoarthritis yanyatheliswa kuyi- International Journal of Medical Sciences . Kwakukhona abahlanganyeli abangu-60 abafundwa yi-100 mg.
Aflapin noma placebo. U-Aflapin watholakala ekuthuthukiseni ubuhlungu nokusebenza ngokomzimba, ezinsukwini ezimbalwa ezinhlanu.
Imiphumela emibi, izixwayiso, nezincomo ze-Boswellia
Abantu abanolwazi oluthile lokuzivikela ku-Boswellia kufanele bagweme imikhiqizo equkethe noma amalungu omndeni wakwaBurseraceae. Ngokuvamile, i-Boswellia ithathwa njengokuphephile uma isetshenziselwa ukuqondiswa, ngaphandle uma kunezifo ezithathelwanayo. Eminye imiphumela emibi evuliwe kwizifundo ifaka i-nausea ne- reflux ye-asidi . Kodwa-ke, ukuphepha nobuthi be-Boswellia akubhekwa njengokucatshangelwa kahle. I-Dermatitis nayo yenzeke ekuvivinyweni komtholampilo komkhiqizo oqukethe i-Boswellia serrata, kodwa kungenzeka ukuthi ngenxa yezinye izithako.
Ukusetshenziswa okuphephile kwe-Boswellia ngesikhathi sokukhulelwa kungakafundiwe, ngakho-ke akukhuthazwa abesifazane abakhulelwe. U-Boswellia naye akazange afundiswe ezinganeni.
Uma ucabangela ukusebenzisa i-Boswellia, njengokunye nokwelapha, qiniseka ukuthi ukhuluma nodokotela wakho kuqala.
Imithombo:
I-Supplement Guide: I-Frankincense yaseNdiya. I-Arthritis Namuhla. Kufinyelele ngo 02/20/2013.
Boswellia (Boswellia serrata). Umuthi wezemvelo AZ. Kufinyelele ngo 02/20/2013.
Ukusebenza nokubekezela kwe-Boswellia serrata kukhishwe ekwelapheni i-osteoarthritis yamadolo - isilingo esilawulwayo se-placebo esilawulwa ngokungahleliwe. UKimmatkar N. et al. I-Phytomedicine. Januwari 2003.
Ukuhlolwa kwe-clinical okuvuliwe, okungahleliwe, okulawulwa ngokungenakulinganiswa kwe-Boswellia serrata uma kuqhathaniswa ne-valdecoxib e-osteoarthritis yamadolo. Xhumana noS et al. I-Indian Journal ye-Pharmacology. 2007; 39: 27-9.
I-blind blind double, i-randomised, i-placebo elawulwa ngokucophelela kokusebenza nokuphepha kwe-5-Loxin yokwelashwa kwe-osteoarthritis yamadolo. I-Arthritis Research Therapy. Julayi 2008.
Ukuphumelela kokuqhathanisa nokubekezelelana kwe-5-Loxin isikhangiso Aflapin ngokumelene ne-osteoarthritis yamadolo: isifundo somtholampilo esilawulwa ngokungahleliwe, esine-placebo, esilawulwayo. I-Sengupta K et al. I-International Journal of Medical Sciences. Novemba, 2010.
Ucwaningo oluthile lwe-clinical control, oluhleliwe, oluhleliwe, olwenziwe ngezikhathi ezithile, luhlola ukuphumelela kokuqala kwe-Aflapin ngezihloko ezine-osteoarthritis yamadolo. Vishall AA et al. I-International Journal of Medical Sciences. Okthoba 12, 2011.